All

Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications
24 September 2024

Sequentia Biotech Secures €10million Equity Investment from Seventure Partners and the EIC Fund to Boost Bioinformatic Solutions for Clinical, Industrial and Research Applications

Sequentia Biotech, a #deeptech and leading bioinformatics company focused on the analysis and application of omics data, announces a €10million Series A, led by Seventure...

Read more
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
23 September 2024

European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement

The European Microbiome Innovation for Health (EMIH) association today announced an agreement between the Microbiome Therapeutics Innovation Group (MTIG) and EMIH for a...

Read more
Water recycling: Chemdoc Water Technologies boosts its financial resources
28 August 2024

Water recycling: Chemdoc Water Technologies boosts its financial resources

4.5 million euros. On July 10, Chemdoc Water Technologies, a small business in the Herault region specializing in the manufacture of equipment for the treatment of industrial...

Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
27 August 2024

Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies

Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Company Secures Additional Financing...

Read more
Biotech: why Singapore’s Allozymes is setting up its European subsidiary in Toulouse
21 August 2024

Biotech: why Singapore’s Allozymes is setting up its European subsidiary in Toulouse

Allozymes, a leading innovator in the discovery and engineering of enzymes (proteins acting as catalysts in all living organisms) for the food and chemical industries, has...

CITRYLL ANNOUNCES COMPLETION OF PATIENT ENROLMENT AND DOSING IN THE REPEAT DOSING STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY DRUG, CIT-013
31 July 2024

CITRYLL ANNOUNCES COMPLETION OF PATIENT ENROLMENT AND DOSING IN THE REPEAT DOSING STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY DRUG, CIT-013

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces the successful completion of...

Read the press release
Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer
27 June 2024

Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer

Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the...

Read more
Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.
20 June 2024

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.

Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial. The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC)...

Read the press release